Overview of Monoclonal Antibody Therapies

Gray, Juliet; Sondel, Paul M.

doi:10.1007/978-3-319-43486-5_4

Cited by 1 publication

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This approach significantly reduces the production of HAMA responses compared to “murine mAbs,” but in some cases, such as Centicor/JNJ's Remicade (infliximab), human antichimeric antibody (HACA) responses have been observed that can lead to some problems and decrease mAb efficiency. Humanized mAbs with the suffix “-zumab” are designed so that only immunoglobulin complementary determining regions (CDRs) are derived from the mouse origin, and the rest of the molecule is derived from a human source [ 9 – 11 ]. Therefore, this strategy significantly leads to a decrease in the development of HAMA and HACA responses.…”

Section: Introductionmentioning

confidence: 99%

“…Today, thanks to the tremendous technological advances in the production of antibodies, our increased knowledge of the pathogenesis of many diseases, as well as the approach of physicians to personalized medicine, has led to the dramatic growth of the production of these MTA products [ 9 ]. Therefore, many countries spend millions of dollars every year to purchase MTA [ 4 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025

Golpour

Vatanpour

Amini³

et al. 2021

Advances in Pharmacological and Pharmaceutical Sciences

View full text Add to dashboard Cite

Background. Monoclonal antibodies with high efficiency and specificity are one of the best strategies to diagnose and treat a variety of diseases such as cancer, autoimmunity, and inflammatory diseases. The market for monoclonal therapeutic antibodies (MTAs) has grown dramatically in the past decade. Objective. Given the importance of these issues, developing countries spend a high cost on importing or producing MTAs annually. This study intends to examine the market of monoclonal therapeutic antibodies in Iran and predict the future growth rate of this market using the obtained data. Methods. Data on the status of MTAs in the country (from 2008 to 2018) were obtained from the Food and Drug Deputy of Mazandaran University of Medical Sciences. The market status of MTAs was studied based on the dosage forms, application, and price. Then, the market outlook was predicted up to year 2025. Results. The results showed that 58.8% of all MTAs were humanized, and 86% of all antibody-based drugs were used to treat cancer. Sales of MTA-based medications will reach $454 million by 2025 and are projected to grow significantly in the future. Conclusion. Given the increasing technology of the production of MTAs and their use in targeted therapies worldwide, their consumption market in Iran is expected to grow significantly.

show abstract

Section: Introductionmentioning

confidence: 99%